Rituximab Prevents the Development of Experimental Autoimmune Encephalomyelitis (EAE): Comparison with Prophylactic, Therapeutic or Combinational Regimens

Rituximab Prevents the Development of Experimental Autoimmune Encephalomyelitis (EAE): Comparison with Prophylactic, Therapeutic or Combinational Regimens

Mena R Al-ani,1 Tom K Raju,2 Mahmood Y Hachim,1,2 Ibrahim Y Hachim,1 Noha M Elemam,1,2 Maha Guimei,1,3 Riyad Bendardaf,4 Azzam A Maghazachi1,2 1Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, 27272, United Arabs Emirates; 2Sharjah Institute for Medical Research...

Full description

Bibliographic Details
Main Authors:	Al-ani MR, Raju TK, Hachim MY, Hachim IY, Elemam NM, Guimei M, Bendardaf R, Maghazachi AA
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-03-01
Series:	Journal of Inflammation Research
Subjects:	rituximab inflammation prevention prophylactic therapeutic t cells b cells in silico bioinformatics immunohistochemistry
Online Access:	https://www.dovepress.com/rituximab-prevents-the-development-of-experimental-autoimmune-encephal-peer-reviewed-article-JIR

Similar Items

Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions
by: Mauro Alaibac
Published: (2018-04-01)

Rituximab in Membranous Nephropathy
by: Philipp Gauckler, et al.
Published: (2021-04-01)

Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen
by: Vivien Hébert, et al.
Published: (2019-08-01)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
by: Elena Treppo, et al.
Published: (2021-08-01)

A modified regimen of rituximab in pemphigus: A retrospective study
by: Tanvi Pradeep Vaidya, et al.
Published: (2020-01-01)

Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen
by: Vivien Hébert, et al.
Published: (2021-05-01)

Toxicogenomic analysis of publicly available transcriptomic data can predict food, drugs, and chemical-induced asthma
by: Hachim MY, et al.
Published: (2019-08-01)

Rituximab and Fibrillary Glomerulonephritis: Interest of B Cell Reconstitution Monitoring
by: Claire Leibler, et al.
Published: (2018-11-01)

Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation
by: Natalie Eaton, et al.
Published: (2018-03-01)

Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E
by: Marten Schulz, et al.
Published: (2020-01-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome
by: Ji Hyun Kim, et al.
Published: (2017-09-01)

Comparison of post cesarean infection after single dose versus three doses of prophylactic antibiotic regimen
by: Farnaz Mohammadian, et al.
Published: (2013-04-01)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
by: Yusuke Miyazaki, et al.
Published: (2020-06-01)

Administration of monoclonal antibodies to b-lymphocytes (rituximab) in rheumatoid arthritis in Russia
by: E L Nasonov, et al.
Published: (2008-08-01)

Rituximab: historia, farmacología y perspectivas Rituximab: history, pharmacology and perspectives
by: Edgardo E. Espinosa Estrada, et al.
Published: (2010-12-01)

Exosomes from GM-CSF expressing embryonic stem cells are an effective prophylactic vaccine for cancer prevention
by: Kavitha Yaddanapudi, et al.
Published: (2019-03-01)

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease
by: Joanna Tieu, et al.
Published: (2021-05-01)

B cells and immunoglobulin in ABO-incompatible renal transplant patients receiving rituximab and double filtration plasmapheresis
by: Meng-Kun Tsai, et al.
Published: (2015-04-01)

Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab
by: Meryl Waldman, et al.
Published: (2016-07-01)

Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab
by: A V Torgashina
Published: (2009-04-01)

Are prophylactic antibiotics indicated for endoscopic retrograde cholangiopancreatography?
by: Brand, Martin
Published: (2011)

Ten-year experience with rituximab for induction and maintenance therapy in patients with ANCA-associated systemic vasculitis
by: T. V. Beketova, et al.
Published: (2020-03-01)

Short-term absolute B-cell counts monitoring in systemic sclerosis patients treated with rituximab
by: L. P. Ananieva, et al.
Published: (2020-09-01)

Small cell bladder cancer: should we consider prophylactic cranial irradiation?
by: Tara Nikonow Morgan, et al.

Optimizing prophylactic antibiotic regimen in patients admitted for transrectal ultrasound-guided prostate biopsies: A prospective randomized study
by: Ahmed Fahmy, et al.
Published: (2016-09-01)

Prophylactic antibiotherapy in Neurosurgery
by: G. Iacob, et al.
Published: (2010-09-01)

Rituximab Therapy for Primary Sjögren’s Syndrome
by: Yi Han Chen, et al.
Published: (2021-09-01)

Rituximab Iodination Procedure for Radioiodinated Rituximab (131I-Rituximab) Preparation
by: Martalena Ramli, et al.
Published: (2019-06-01)

10-year personal experience of rituximab use in nephrological patients
by: D.D. Ivanov, et al.
Published: (2020-03-01)

Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
by: T. V. Beketova, et al.
Published: (2020-09-01)

Rituximab treatment efficacy in a patient with systemic lupus erythematosus with severe thrombocytopenia
by: Alexandrova O.L., et al.
Published: (2018-09-01)

Prevalence of hyperuricemia in children with leukemia and lymphoma with respect to prophylactic treatment
by: Oloomi Z, et al.
Published: (2007-06-01)

Rituximab: A viable treatment option for epoetin-induced pure red cell aplasia
by: S A Mahajan, et al.
Published: (2015-01-01)

How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas
by: Mohammed R, et al.
Published: (2019-02-01)

USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS
by: Anna Vasilyevna Torgashina, et al.
Published: (2010-08-01)

EXPERIENCE WITH RITUXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Mikhail Sergeyevich Protopopov, et al.
Published: (2013-02-01)

Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience
by: M Surendra, et al.
Published: (2016-01-01)

Good response to rituximab in a patient with granulomatosis with polyangiitis and pulmonary, renal manifestations and ophthalmoplegia.
by: Carolina Díez-Morrondo, et al.
Published: (2016-01-01)

Cannot write session to /tmp/vufind_sessions/sess_32qjmak1hvr7jdfpegckbckppd